Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
20.18
-0.91 (-4.31%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein-coupled receptors (GPCRs).
It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. is headquartered in Watertown, Massachusetts.
Tectonic Therapeutic, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Alise Reicin |
Contact Details
Address: 490 Arsenal Way, Suite 210 Watertown, Massachusetts 02472 United States | |
| Phone | 339 666 3320 |
| Website | tectonictx.com |
Stock Details
| Ticker Symbol | TECX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681087 |
| CUSIP Number | 878972108 |
| ISIN Number | US8789721086 |
| Employer ID | 81-0710585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Dr. Timothy A. Springer M.B.A., Ph.D. | Independent Director |
| Daniel Lochner M.B.A. | Chief Financial Officer |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer |
| Barry Rubenstein M.S. | Senior Vice President of People and Culture |
| Anthony Muslin M.D. | Chief Development Officer |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer |
| John Diener | Senior Vice President of Antibody Engineering and Protein Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 3, 2025 | EFFECT | Notice of Effectiveness |
| Apr 2, 2025 | EFFECT | Notice of Effectiveness |
| Mar 27, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 26, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |